Skip to main content
. Author manuscript; available in PMC: 2010 Apr 13.
Published in final edited form as: Eye (Lond). 2008 Dec 19;23(10):1946–1953. doi: 10.1038/eye.2008.379

Table 2.

Literature summary of KLAL for total LSCD

Authors Cases Median FU
(months)		 Visual
improvement (%)		 Surface
improvement (%)		 Immunosuppression
Dua and Azuara-Blanco60 6 11.8   84 100 Tacrolimus
Tsubota et al61 9 12 100 100 CsA
Dexamethasone
Tan et al55 9 14 100   77 CsA
Gomes et al35 10 16.7   40   20 CsA
Prednisone
Tsai and Tseng56 16 18.5   82 100 CsA
Tsubota et al63 43 23   60   51 CsA
Dexamethasone
Holland64 25 27   66   62 CsA
Solomon et al65 39 34   44.6   23.7 CsA
Holland et al66 31 36   83.9   74.2 CsA
Prednisone
Maruyama-Hosoi et al69 85 46   NA   55.3 CsA
Ilari and Daya67 23 60   43.5   27.3 CsA
Shimazaki et al68 29 72   48   45 CsA
Dexamethasone

CsA = cyclosporine A; FU = follow-up; KLAL = keratolimbal allograft; LSCD = limbal stem cell deficiency.

Improved surface is defined as epithelialization and improvement in corneal clarity and smoothness.